Intravenous Nimodipine West European Stroke Trial "INWEST"

Terminated

Phase N/A Results

Trial Description

To evaluate whether intravenously administered nimodipine for a period of 5 days, followed by oral nimodipine until day 21, improves neurological and functional outcome in acute ischemic stroke patients.

Interventions

  • Nimodipine (NimotopĀ®)Drug
    Intervention Desc: Calcium channel blocker (L-type calcium channels)

Trial Design

Randomized, double-blind, placebo-controlled trial of 295 patients at 34 centers.

Patient Involvement

Patients were randomized to receive 1 or 2 mg/h intravenous nimodipine or placebo for 5 days. This was followed by 16 days of treatment with oral nimodipine (30 mg four times daily) or placebo. Patients were assessed at baseline and on days 1, 2, 3, 5, 7, and 21 of treatment as well as weeks 12 and 24 after entry.

Outcomes

Type Measure Time Frame Safety Issue
Primary Neurological status as assessed by the Orgogozo scale and functional status as assessed by Barthel Index at day 21.
Secondary Orgogozo, Mathew scale and Barthel Index scores at weeks 12 and 24.

Sponsors

Bayer AG